Drug Product

Type: Keyphrase
Name: Drug Product
First reported 3 hours ago - Updated 3 hours ago - 1 reports

Marketing Firm XL Alliance Named 2014 MM&M Award Finalist for "Best Multicultural Campaign" for Caladryl®

About Caladryl®CALADRYL® Anti-Itch Lotion is a skin protectant and topical analgesic drug product. It temporarily relieves pain and itching associated with rashes, insect bites, minor skin irritation and minor cuts; and dries the oozing and weeping of ... [Published Indianapolis Business Journal - 3 hours ago]
First reported Aug 30 2014 - Updated Aug 30 2014 - 1 reports

Moving From Quality Control To Quality Assurance

By Guy Wingate, PhDThis article is based on content from the presentation, “Moving from Quality Control to Quality Assurance” held during the ISPE Proactive Compliance Conference on 13-14 January 2014 by Dr. Guy Wingate, VP and Compliance Officer (Global ... [Published Pharmaceutical Online - Aug 30 2014]
First reported Aug 30 2014 - Updated Aug 30 2014 - 1 reports

Research Scientist II

Gilead Sciences, Inc. is a research-based biopharmaceutical company founded in 1987. Together we deliver life-saving therapies to patients in need. With the commitment and drive you bring to the workplace every day, you will be part of a team that is ... [Published PharmaDiversity - Aug 30 2014]
First reported Aug 28 2014 - Updated Aug 29 2014 - 1 reports

Pfizer and Protalix BioTherapeutics Announce FDA -2-

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix's unique expression system presents ... [Published Scottrade - Aug 28 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

GMOs in Food and Medicine: An Overview

Originally posted on  SkeptiForum .When you search online for “GMOs” (Genetically Modified Organisms) the results that come up speak to GM crops, but GMOs are more than just plants. The technology of genetic modification or  genetic engineering  was first ... [Published GMOAnswers - Aug 29 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

CAMBREX : to Exhibit at CPhI Worldwide 2014

Release date- 26082014 - East Rutherford, NJ - Cambrex Corporation (NYSE: CBM, ' Cambrex ') will be exhibiting at CPhI Worldwide 2014, October 7 - 9 in Paris Nord Villepinte, France .Conference delegates are warmly invited to visit Cambrex's booth to ... [Published 4 Traders - Aug 28 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Manager, CMO EU Operations

SUMMARY DESCRIPTIONThe Manager, EU Operations is responsible for supporting small molecule drug product manufacturing for clinical and commercial products. Primary activity is to manage overall manufacturing operations including the development, planning, ... [Published PharmaDiversity - Aug 28 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Director Pharmaceutical Sciences

This position will report to the Head of Technical Operations & Global Supply Chain. The individual will provide expertise, strategy, and broad experience in formulation and product development from early phase through product registration. . Primary ... [Published PharmaDiversity - Aug 27 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Jaguar Animal Health IPO

Jaguar Animal Health Inc. filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). No terms were given for the offering, but it is valued up to $70 million. The company will list its common stock on the Nasdaq ... [Published 24/7 Wall St - Aug 27 2014]
First reported Aug 26 2014 - Updated Aug 27 2014 - 1 reports

Research and Markets: Active Pharmaceutical Ingredients Global Market - Forecast to 2020

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/nd7hcd/active) has announced the addition of the "Active Pharmaceutical Ingredients Global Market - Forecast to 2020" report to their offering. Active Pharmaceutical ... [Published Business Wire Health News - Aug 26 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Concert Pharma secures $2m payment for new drug product AVP-786

Concert Pharmaceuticals has received a $2m milestone as part of a development and license agreement with Avanir Pharmaceuticals for the clinical progression of AVP-786 in patients with major depressive disorder (MDD). ... [Published PBR - News - Aug 27 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

That's Nice Announces Expanded Offering For Strategic Content And Public Relations

As Global Director of Marketing for Pharmaceutical Products at DSM, Tiene gained over six years of experience overseeing strategic positioning and communications for a biologics business providing mammalian cell culture-based recombinant proteins and ... [Published Pettinga Financial Advisors - Aug 26 2014]

Quotes

...who-is-who panel of agencies," said Liliana Gil Valletta, Managing Partner and CO-Founder of XL Alliance and a former Johnson & Johnson executive. "We praise Valeant's leadership in recognizing the power of the Hispanic market as a source of incremental growth to revive the brand's emotional benefit to American moms. We feel strongly the market opportunity combined with our unique multicultural, digital and healthcare capability have translated into a fresh take into the brand's story and emotional connection to moms, particularly Hispanic."
...the scientists, clinical investigators, and FDA for working with us to develop AST-OPC1," said Pedro Lichtinger, President and CEO of Asterias. "We are especially enthusiastic about working with our new partner, CIRM, in executing this clinical trial. The FDA clearance provides Asterias with imminent access to the previously announced $14.3 million CIRM grant, which provides non-dilutive funding to support both the clinical trial and other product development activities for AST-OPC1."
Release date- 26082014 - East Rutherford, NJ - Cambrex Corporation (NYSE: CBM, " Cambrex ') will be exhibiting at CPhI Worldwide 2014, October 7 - 9 in Paris Nord Villepinte, France ."
Supplementing the background information on this patent, NewsRx reporters also obtained the inventors' summary information for this patent: "Problems to be Solved by the Invention"

More Content

All (355) | News (256) | Reports (0) | Blogs (93) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Marketing Firm XL Alliance Named 2014 MM&M Awar... [Published Indianapolis Business Journal - 3 hours ago]
Marketing Firm XL Alliance Named 2014 MM&M Awar... [Published Finwin - 3 hours ago]
FDA Strategies Designed to Speed Generic Drug A... [Published PharmTech.com - 4 hours ago]
BioTime: Asterias Biotherapeutics to Initiate P... [Published Individual.com - 10 hours ago]
Supply Chain Security Tops Concerns for Biophar... [Published PharmTech.com - 10 hours ago]
Contract Providers Assume Expanded Responsibili... [Published PharmTech.com - 10 hours ago]
Moving From Quality Control To Quality Assurance [Published Pharmaceutical Online - Aug 30 2014]
Scientist 2, Formulation [Published PharmaDiversity - Aug 30 2014]
Research Scientist II [Published PharmaDiversity - Aug 30 2014]
Director of Regulatory Affairs - CMC [Published PharmaDiversity - Aug 29 2014]
GMOs in Food and Medicine: An Overview [Published GMOAnswers - Aug 29 2014]
Children's National Health System Hosts Second ... [Published Digital Journal - Aug 28 2014]
Pfizer and Protalix BioTherapeutics Announce FD... [Published Scottrade - Aug 28 2014]
CAMBREX : to Exhibit at CPhI Worldwide 2014 [Published 4 Traders - Aug 28 2014]
Senior Research Associate II - Biologics Formul... [Published PharmaDiversity - Aug 28 2014]
Associate Director, Quality [Published PharmaDiversity - Aug 28 2014]
BIOSYENT : Reports Q2 and 6 Month Results [Published 4 Traders - Aug 28 2014]
Patent Issued for Production Method of 11-Sugar... [Published HispanicBusiness.com - Aug 28 2014]
Manager, CMO EU Operations [Published PharmaDiversity - Aug 28 2014]
Lannett's (LCI) CEO Arthur Bedrosian on 2014 Re... [Published Seeking Alpha - Aug 28 2014]
Cubist Pharmaceuticals : Researchers Submit Pat... [Published 4 Traders - Aug 28 2014]
Senior Scientist, Analytical Sciences [Published PharmaDiversity - Aug 28 2014]
Director Pharmaceutical Sciences [Published PharmaDiversity - Aug 27 2014]
Jaguar Animal Health files for $70 million init... [Published Individual.com - Aug 27 2014]
Jaguar Animal Health IPO [Published 24/7 Wall St - Aug 27 2014]
Concert Pharma secures $2m payment for new drug... [Published PBR - News - Aug 27 2014]
FDA Puts Controls on Controlled Correspondence ... [Published FDA Law Blog - Aug 27 2014]
Who can Recall what FDA’s Mandatory Recall Auth... [Published FDA Law Blog - Aug 27 2014]
Research and Markets: Active Pharmaceutical Ing... [Published Business Wire Health News - Aug 26 2014]
Your E-cigarette Exclusive [Published Mens Health South Africa - Aug 26 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Concert Pharma secures $2m payment for new drug... [Published PBR - News - Aug 27 2014]
Concert Pharmaceuticals has received a $2m milestone as part of a development and license agreement with Avanir Pharmaceuticals for the clinical progression of AVP-786 in patients with major depressive disorder (MDD). ...
FDA Puts Controls on Controlled Correspondence ... [Published FDA Law Blog - Aug 27 2014]
By Kurt R. Karst –This blogger’s oldest child started middle school this past week.  Naturally, I was excited to get his impressions of the first day of school.  “Good” was his initial comment – a now all to familiar one-word tween response.  So I pressed ...
Who can Recall what FDA’s Mandatory Recall Auth... [Published FDA Law Blog - Aug 27 2014]
By David C. Gibbons –It is rare that we urge our readers to keep a copy of a court ruling or brief.  A Brief that FDA filed on August 21, 2014 is an exception.  Companies and others should read this brief and keep it close at hand. When someone wants ...
Research and Markets: Active Pharmaceutical Ing... [Published Business Wire Health News - Aug 26 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/nd7hcd/active) has announced the addition of the "Active Pharmaceutical Ingredients Global Market - Forecast to 2020" report to their offering. Active Pharmaceutical ...
Civitas Therapeutics scores $55 mln Series C [Published PE Hub Blog - Aug 26 2014]
Civitas Therapeutics has closed $55 million in Series C funding. The investors included Adage Capital Management, OrbiMed Advisors, Partner Fund Management, Rock Springs Capital, Sofinnova Ventures, Alkermes plc, Bay City Capital, Canaan Partners, ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Ohr Pharmaceutical Announces Agreement to Acqui... [Published GlobeNewswire: Acquisitions News - May 15 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.